StockpollyBeta
Get App
Popularity #4,914
CLRB · NASDAQ · Biotechnology

Cellectar Biosciences (CLRB)

Develops targeted radiotherapeutics for cancer through a phospholipid drug conjugate platform.

$2.15
vs last close−0.08 (−3.81%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
91312141313665667
Research & development787756323335
255687342333
General & administrative255687342303
Operating income−9−13−12−14−13−13−6−6−5−6−6−7
−85−1513−110010000
Interest income000000000000
Other non-operating income0−515−131−100−10000
Income before tax−18−8−27−1−15−2−7−5−4−5−6−7
Income tax expense000000000000
Net income from continuing operations−18−8−27−1−15−2−7−5−4−5−6−7
Net income−18−8−27−1−15−2−7−5−4−5−6−7
EPS, basic−$46.48−$12.17−$27.24−$0.77−$11.18−$1.68−$4.30−$3.39−$1.41−$1.25−$1.33−$0.57
EPS, diluted−$46.48−$12.17−$27.24−$5.43−$11.18−$1.68−$4.30−$3.39−$1.41−$1.25−$1.33−$0.57
Weighted average shares, basic0110112234412
Weighted average shares, diluted0111112234412
EBITDA−9−8−27−1−15−2−7−5−4−5−6−7
Depreciation & amortization000000000000
EBIT−9−8−27−1−15−2−7−5−4−5−6−7